Latest News

Epigenomics AG: Life Technologies to Supply Crucial Components for Second-Generation Colorectal Cancer Blood Test


Berlin, Germany, and Seattle, WA, U.S.A., May 6, 2011

Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnosis company, today announced the signing of a supply agreement with Life Technologies Corporation, a global provider of innovative life science solutions. As the Original Equipment Manufacturer (OEM) Life Technologies will supply its DynabeadsproColonproColon 2.0 requires fewer components and handling steps, and can reach results within eight hours, making it easier to automate on a wide range of IVD automation solutions. A key feature of the new product is the use of Dynabeads-NA complex can be separated and the NAs concentrated for diagnostic analysis such as the detection of methylated DNA of the SEPT9 gene, the biomarker that is targeted by Epi proColon 2.0. DynabeadsproColon proColonproColon 2.0 assay to its contract manufacturer NextPharma based in San Diego, CA, U.S.A. Epigenomics plans to conduct analytical and clinical validation studies in the second half of 2011. The company expects to submit a pre-market approval application (PMA) for Epi proColon 2.0 to the FDA before year-end 2011.

Contact Epigenomics AG

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368

About Epigenomics


Epigenomics legal disclaimer. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.